BCM
AIM

Bridgeway Capital Management’s AIM ImmunoTech AIM Stock Holding History

Bridgeway Capital Management’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-110
Closed -$2.97K – 1336
2024
Q3 		$2.97K Sell
110
-780
-88% -$26K ﹤0.01% 1253
2024
Q2 		$33.1K Sell
890
-200
-18% -$8.49K ﹤0.01% 1245
2024
Q1 		$51.3K Hold
1,090
– – ﹤0.01% 1264
2023
Q4 		$47.9K Hold
1,090
– – ﹤0.01% 1316
2023
Q3 		$49.5K Hold
1,090
– – ﹤0.01% 1306
2023
Q2 		$73K Hold
1,090
– – ﹤0.01% 1298
2023
Q1 		$46.8K Sell
1,090
-422
-28% -$21.9K ﹤0.01% 1316
2022
Q4 		$47.1K Hold
1,512
– – ﹤0.01% 1304
2022
Q3 		$88K Hold
1,512
– – ﹤0.01% 1298
2022
Q2 		$118K Sell
1,512
-100
-6% -$9.6K ﹤0.01% 1197
2022
Q1 		$171K Sell
1,612
-550
-25% -$47.4K ﹤0.01% 1195
2021
Q4 		$199K Sell
2,162
-200
-8% -$30.9K ﹤0.01% 1164
2021
Q3 		$477K Sell
2,362
-100
-4% -$20.2K 0.01% 1046
2021
Q2 		$529K Sell
2,462
-251
-9% -$53.8K 0.01% 1051
2021
Q1 		$615K Buy
2,713
+1,602
+144% +$362K 0.01% 1042
2020
Q4 		$199K Buy
+1,111
New +$222K ﹤0.01% 1210

Other funds holding AIM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Bridgeway Capital Management's AIM Position: Q4 2024 in Review

Bridgeway Capital Management sold out of AIM ImmunoTech (AIM) in Q4 2024, closing a stake of 110 shares — an estimated $2.97K sold.

Bridgeway Capital Management first reported a position in AIM in Q4 2020 and held it in 16 quarters. The position peaked at $615K in Q1 2021. 32 funds tracked by Wall St. Rank hold AIM as of Q4 2024.

  • Bridgeway Capital Management reported no remaining AIM ImmunoTech position as of Q4 2024 after selling out during the quarter.
  • Bridgeway Capital Management sold 110 AIM ImmunoTech shares in Q4 2024, an estimated $2.97K.
  • Bridgeway Capital Management first reported a position in AIM ImmunoTech in Q4 2020 and held it in 16 quarters.
  • Bridgeway Capital Management's AIM ImmunoTech position peaked at $615K in Q1 2021.
  • 32 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q4 2024.

Based on Bridgeway Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.